NASDAQ:CTMX - CytomX Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$25.93 +0.19 (+0.74 %)
(As of 05/25/2018 08:59 AM ET)
Previous Close$25.74
Today's Range$25.63 - $26.40
52-Week Range$13.00 - $35.00
Volume209,575 shs
Average Volume331,596 shs
Market Capitalization$1.00 billion
P/E Ratio-22.35
Dividend YieldN/A
Beta0.95

About CytomX Therapeutics (NASDAQ:CTMX)

CytomX Therapeutics logoCytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Bristol-Myers Squibb Company, ImmunoGen, Inc., MD Anderson, and Pfizer Inc. to develop Probody therapeutics. It also has a strategic collaboration with Amgen, Inc. to develop T cell-bispecific probody therapeutic targeting epidermal growth factor receptor-CD3. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Receive CTMX News and Ratings via Email

Sign-up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CTMX
CUSIPN/A
Phone650-515-3185

Debt

Debt-to-Equity RatioN/A
Current Ratio5.27
Quick Ratio5.27

Price-To-Earnings

Trailing P/E Ratio-22.35
Forward P/E Ratio-16.95
P/E GrowthN/A

Sales & Book Value

Annual Sales$71.62 million
Price / Sales14.11
Cash FlowN/A
Price / CashN/A
Book Value$1.27 per share
Price / Book20.42

Profitability

EPS (Most Recent Fiscal Year)($1.16)
Net Income$-43,090,000.00
Net Margins-67.88%
Return on Equity-92.68%
Return on Assets-13.31%

Miscellaneous

Employees93
Outstanding Shares38,960,000

CytomX Therapeutics (NASDAQ:CTMX) Frequently Asked Questions

What is CytomX Therapeutics' stock symbol?

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

How were CytomX Therapeutics' earnings last quarter?

CytomX Therapeutics (NASDAQ:CTMX) released its quarterly earnings results on Wednesday, March, 7th. The biotechnology company reported $0.02 EPS for the quarter, topping analysts' consensus estimates of ($0.43) by $0.45. The biotechnology company had revenue of $27.07 million for the quarter, compared to the consensus estimate of $10.70 million. CytomX Therapeutics had a negative net margin of 67.88% and a negative return on equity of 92.68%. View CytomX Therapeutics' Earnings History.

When is CytomX Therapeutics' next earnings date?

CytomX Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for CytomX Therapeutics.

What price target have analysts set for CTMX?

9 equities research analysts have issued 1-year price objectives for CytomX Therapeutics' shares. Their predictions range from $37.00 to $44.00. On average, they anticipate CytomX Therapeutics' stock price to reach $40.1667 in the next year. View Analyst Ratings for CytomX Therapeutics.

What are Wall Street analysts saying about CytomX Therapeutics stock?

Here are some recent quotes from research analysts about CytomX Therapeutics stock:
  • 1. According to Zacks Investment Research, "CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. " (5/10/2018)
  • 2. Cann analysts commented, "Loss per share was $0.69, compared to our estimate of $0.56. This was the result of higher than expected R&D expense of $28.1 million compared to our estimate of $15.2 million, which resulted from a $10 million payment to UCSB for a sublicense payment. This was partially offset by higher than estimated revenue of $8.8 million compared to our estimated $1.0 million." (8/8/2017)

Who are some of CytomX Therapeutics' key competitors?

Who are CytomX Therapeutics' key executives?

CytomX Therapeutics' management team includes the folowing people:
  • Dr. Sean A. McCarthy, Pres, CEO & Director (Age 51)
  • Mr. Frederick W. Gluck, Co-Founder & Director (Age 83)
  • Dr. W. Michael Kavanaugh M.D., Chief Scientific Officer and Head of Research & Non-Clinical Devel. (Age 62)
  • Dr. Rachel Wallach Humphrey, Chief Medical Officer (Age 57)
  • Prof. Patrick S. Daugherty Ph.D., Founder and Member of Scientific Advisory Board

Has CytomX Therapeutics been receiving favorable news coverage?

News articles about CTMX stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. CytomX Therapeutics earned a media sentiment score of 0.21 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 44.30 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are CytomX Therapeutics' major shareholders?

CytomX Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.45%), Millennium Management LLC (1.53%), FIL Ltd (1.10%), Redmile Group LLC (0.86%), Spark Investment Management LLC (0.75%) and American Century Companies Inc. (0.53%). Company insiders that own CytomX Therapeutics stock include Debanjan Ray, Frederick W Gluck, Ix LP Canaan, Kevin P Starr, Rachel Humphrey, Robert C Goeltz II, Robert I Tepper, Rock Ventures Lp Third, Sean A Mccarthy, Timothy M Shannon and William Michael Kavanaugh. View Institutional Ownership Trends for CytomX Therapeutics.

Which institutional investors are selling CytomX Therapeutics stock?

CTMX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc., American Century Companies Inc., Redmile Group LLC, Wells Fargo & Company MN, Candriam Luxembourg S.C.A., JPMorgan Chase & Co. and Schroder Investment Management Group. Company insiders that have sold CytomX Therapeutics company stock in the last year include Debanjan Ray, Frederick W Gluck, Rachel Humphrey, Robert I Tepper, Sean A Mccarthy and William Michael Kavanaugh. View Insider Buying and Selling for CytomX Therapeutics.

Which institutional investors are buying CytomX Therapeutics stock?

CTMX stock was acquired by a variety of institutional investors in the last quarter, including PointState Capital LP, Victory Capital Management Inc., FIL Ltd, Russell Investments Group Ltd., Federated Investors Inc. PA, Spark Investment Management LLC, Citadel Advisors LLC and UBS Group AG. View Insider Buying and Selling for CytomX Therapeutics.

How do I buy shares of CytomX Therapeutics?

Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CytomX Therapeutics' stock price today?

One share of CTMX stock can currently be purchased for approximately $25.93.

How big of a company is CytomX Therapeutics?

CytomX Therapeutics has a market capitalization of $1.00 billion and generates $71.62 million in revenue each year. The biotechnology company earns $-43,090,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. CytomX Therapeutics employs 93 workers across the globe.

How can I contact CytomX Therapeutics?

CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-515-3185 or via email at [email protected]


MarketBeat Community Rating for CytomX Therapeutics (CTMX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  190 (Vote Outperform)
Underperform Votes:  138 (Vote Underperform)
Total Votes:  328
MarketBeat's community ratings are surveys of what our community members think about CytomX Therapeutics and other stocks. Vote "Outperform" if you believe CTMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTMX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

CytomX Therapeutics (NASDAQ:CTMX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
9 Wall Street analysts have issued ratings and price targets for CytomX Therapeutics in the last 12 months. Their average twelve-month price target is $40.1667, suggesting that the stock has a possible upside of 54.90%. The high price target for CTMX is $44.00 and the low price target for CTMX is $37.00. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.782.802.642.60
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $40.1667$40.1667$33.8750$33.00
Price Target Upside: 54.90% upside18.14% upside48.12% upside64.67% upside

CytomX Therapeutics (NASDAQ:CTMX) Consensus Price Target History

Price Target History for CytomX Therapeutics (NASDAQ:CTMX)

CytomX Therapeutics (NASDAQ:CTMX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/16/2018Cantor FitzgeraldSet Price TargetBuy$40.00HighView Rating Details
5/10/2018CowenReiterated RatingBuyLowView Rating Details
3/8/2018Jefferies GroupBoost Price TargetBuy$40.00HighView Rating Details
3/8/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$34.00 ➝ $40.00HighView Rating Details
1/5/2018CitigroupInitiated CoverageBuy ➝ Buy$40.00HighView Rating Details
10/4/2017OppenheimerReiterated RatingHoldHighView Rating Details
10/4/2017NomuraBoost Price TargetBuy$44.00HighView Rating Details
10/4/2017WedbushSet Price TargetBuy$26.00 ➝ $37.00HighView Rating Details
8/8/2017CannReiterated RatingHoldHighView Rating Details
5/8/2017HC WainwrightReiterated RatingBuyLowView Rating Details
3/20/2017InstinetBoost Price TargetSell$21.00 ➝ $32.00MediumView Rating Details
(Data available from 5/25/2016 forward)

Earnings

CytomX Therapeutics (NASDAQ:CTMX) Earnings History and Estimates Chart

Earnings by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

CytomX Therapeutics (NASDAQ:CTMX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.63)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.27)($0.01)($0.14)
Q2 20182($0.31)($0.11)($0.21)
Q3 20182($0.34)$0.06($0.14)
Q4 20182($0.36)$0.08($0.14)

CytomX Therapeutics (NASDAQ CTMX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018($0.43)N/AView Earnings Details
5/9/2018Q1 2018($0.23)($0.40)$19.77 million$14.18 millionViewN/AView Earnings Details
3/7/2018Q4 2017($0.43)$0.02$10.70 million$27.07 millionViewN/AView Earnings Details
11/7/2017Q3 2017($0.14)($0.28)$16.60 million$24.14 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.39)($0.69)$4.95 million$8.75 millionViewListenView Earnings Details
5/5/2017Q1 2017($0.55)($0.23)$2.10 million$11.65 millionViewN/AView Earnings Details
3/2/2017Q4 2016($0.45)($0.39)$6.27 millionViewN/AView Earnings Details
11/3/2016Q3($0.35)($0.40)$3.20 million$3.45 millionViewN/AView Earnings Details
8/3/2016Q2($0.41)($0.39)$2.10 million$3.09 millionViewN/AView Earnings Details
5/6/2016Q1 2016($0.26)($0.44)$6.00 million$2.22 millionViewN/AView Earnings Details
3/7/2016Q4 2015($0.34)($0.39)$1.75 million$1.99 millionViewN/AView Earnings Details
11/23/2015Q3 2015($0.25)($14.26)$1.75 million$1.94 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

CytomX Therapeutics (NASDAQ:CTMX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

CytomX Therapeutics (NASDAQ CTMX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.50%
Institutional Ownership Percentage: 75.97%
Insider Trading History for CytomX Therapeutics (NASDAQ:CTMX)
Institutional Ownership by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

CytomX Therapeutics (NASDAQ CTMX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/1/2018Debanjan RayCFOSell3,000$26.52$79,560.007,741View SEC Filing  
5/1/2018Sean A MccarthyCEOSell19,578$26.55$519,795.9024,221View SEC Filing  
4/2/2018Debanjan RayCFOSell3,000$28.12$84,360.007,741View SEC Filing  
3/26/2018Frederick W GluckDirectorSell5,000$31.93$159,650.00View SEC Filing  
3/2/2018Debanjan RayCFOSell33,000$29.99$989,670.00View SEC Filing  
3/2/2018Frederick W GluckDirectorSell16,181$30.00$485,430.00View SEC Filing  
3/2/2018Rachel HumphreyInsiderSell16,160$30.00$484,800.0046,394View SEC Filing  
2/28/2018Frederick W GluckDirectorSell3,819$30.00$114,570.00View SEC Filing  
2/28/2018Rachel HumphreyInsiderSell23,840$30.00$715,200.0054,074View SEC Filing  
2/1/2018Debanjan RayCFOSell2,548$26.69$68,006.124,741View SEC Filing  
1/5/2018Frederick W GluckDirectorSell10,000$25.01$250,100.00View SEC Filing  
1/5/2018Sean A MccarthyInsiderSell6,526$25.01$163,215.2611,169View SEC Filing  
1/2/2018Debanjan RayCFOSell2,500$21.11$52,775.00View SEC Filing  
1/2/2018Sean A MccarthyInsiderSell13,052$21.04$274,614.0817,695View SEC Filing  
12/26/2017Frederick W GluckDirectorSell5,000$22.29$111,450.00View SEC Filing  
12/1/2017Debanjan RayCFOSell2,500$20.58$51,450.00View SEC Filing  
12/1/2017Sean A MccarthyInsiderSell14,340$20.60$295,404.00View SEC Filing  
11/1/2017Debanjan RayCFOSell2,500$20.00$50,000.0012,126View SEC Filing  
11/1/2017Sean A MccarthyCEOSell14,342$19.86$284,832.1218,587View SEC Filing  
10/4/2017Frederick W GluckDirectorSell10,000$24.27$242,700.00View SEC Filing  
10/4/2017Robert I TepperMajor ShareholderSell24,777$24.34$603,072.18View SEC Filing  
10/4/2017Sean A MccarthyCEOSell19,120$24.13$461,365.6023,365View SEC Filing  
10/4/2017William Michael KavanaughInsiderSell48,368$24.34$1,177,277.12View SEC Filing  
10/2/2017Debanjan RayCFOSell2,500$18.10$45,250.00View SEC Filing  
10/2/2017Sean A MccarthyInsiderSell9,562$18.57$177,566.34View SEC Filing  
9/26/2017Frederick W GluckDirectorSell5,000$17.30$86,500.00View SEC Filing  
9/19/2017Robert I TepperMajor ShareholderSell20,000$18.00$360,000.0054,293View SEC Filing  
9/1/2017Debanjan RayCFOSell2,500$17.17$42,925.0017,126View SEC Filing  
9/1/2017Sean A MccarthyInsiderSell9,930$17.32$171,987.6014,175View SEC Filing  
8/31/2017Sean A MccarthyInsiderSell18,756$17.50$328,230.0023,001View SEC Filing  
8/9/2017Debanjan RayCFOSell2,500$15.00$37,500.0019,626View SEC Filing  
8/9/2017Sean A MccarthyInsiderSell4,781$15.00$71,715.009,026View SEC Filing  
7/3/2017Debanjan RayCFOSell2,500$15.47$38,675.0022,126View SEC Filing  
7/3/2017Sean A MccarthyInsiderSell4,781$15.52$74,201.129,026View SEC Filing  
6/29/2017Robert I TepperMajor ShareholderSell15,000$16.00$240,000.0044,777View SEC Filing  
6/26/2017Frederick W GluckDirectorSell5,000$14.61$73,050.00View SEC Filing  
6/26/2017Sean A MccarthyInsiderSell4,481$15.00$67,215.008,726View SEC Filing  
6/5/2017Sean A MccarthyInsiderSell300$15.00$4,500.004,545View SEC Filing  
5/1/2017Sean A MccarthyInsiderSell4,781$15.70$75,061.706,760View SEC Filing  
4/12/2017Kevin P StarrMajor ShareholderSell28,357$16.36$463,920.5231,419View SEC Filing  
4/4/2017Sean A MccarthyInsiderSell9,562$17.22$164,657.646,760View SEC Filing  
3/27/2017Rock Ventures Lp ThirdMajor ShareholderSell1,650,000$17.39$28,693,500.00View SEC Filing  
3/20/2017Robert C Goeltz IICFOSell21,517$19.81$426,251.7731,306View SEC Filing  
3/20/2017Sean A MccarthyInsiderSell14,343$19.60$281,122.8016,322View SEC Filing  
3/3/2017Sean A MccarthyInsiderSell14,343$15.00$215,145.0016,322View SEC Filing  
11/28/2016Ix L.P. CanaanDirectorSell38,459$11.56$444,586.04View SEC Filing  
11/22/2016Ix L.P. CanaanDirectorSell42,550$11.71$498,260.50View SEC Filing  
11/21/2016Ix L.P. CanaanDirectorSell45,324$11.61$526,211.64View SEC Filing  
11/16/2016Ix L.P. CanaanDirectorSell51,581$11.50$593,181.50View SEC Filing  
11/15/2016Timothy M ShannonDirectorSell33,064$11.48$379,574.72268View SEC Filing  
11/14/2016Ix L.P. CanaanDirectorSell86,270$11.16$962,773.20View SEC Filing  
11/9/2016Ix L.P. CanaanDirectorSell13,730$11.03$151,441.90View SEC Filing  
6/10/2016Timothy M ShannonDirectorSell48,427$10.07$487,659.89134View SEC Filing  
6/7/2016Ix L.P. CanaanDirectorSell111,498$10.01$1,116,094.98View SEC Filing  
6/3/2016Ix L.P. CanaanDirectorSell59,621$10.80$643,906.80View SEC Filing  
6/1/2016Ix L.P. CanaanDirectorSell22,463$10.75$241,477.25View SEC Filing  
5/27/2016Ix L.P. CanaanDirectorSell25,082$10.60$265,869.20View SEC Filing  
5/26/2016Timothy M ShannonDirectorSell51,343$10.34$530,886.62134View SEC Filing  
5/24/2016Ix L.P. CanaanDirectorSell13,253$10.09$133,722.77View SEC Filing  
5/20/2016Ix L.P. CanaanDirectorSell8,687$10.10$87,738.70View SEC Filing  
10/14/2015Cynthia J LaddVPBuy3,000$12.00$36,000.003,000View SEC Filing  
10/14/2015Frederick W GluckDirectorBuy15,000$12.00$180,000.00147,791View SEC Filing  
10/14/2015James E FlynnInsiderBuy625,000$12.00$7,500,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

CytomX Therapeutics (NASDAQ CTMX) News Headlines

Source:
DateHeadline
FY2018 EPS Estimates for CytomX Therapeutics (CTMX) Cut by Cantor FitzgeraldFY2018 EPS Estimates for CytomX Therapeutics (CTMX) Cut by Cantor Fitzgerald
www.americanbankingnews.com - May 24 at 8:38 AM
Wired News – CytomX Gets FDA Approval for Investigational New Drug Application, Triggers $25 Million Milestone Payment from AbbVieWired News – CytomX Gets FDA Approval for Investigational New Drug Application, Triggers $25 Million Milestone Payment from AbbVie
finance.yahoo.com - May 24 at 8:16 AM
CytomX earns $25M milestone from AbbVie on CX-2029 INDCytomX earns $25M milestone from AbbVie on CX-2029 IND
seekingalpha.com - May 22 at 8:17 AM
CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-2029, a CD71-Directed Probody TherapeuticCytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-2029, a CD71-Directed Probody Therapeutic
finance.yahoo.com - May 22 at 8:17 AM
CytomX: X Marks The Spot Of ReversalCytomX: X Marks The Spot Of Reversal
seekingalpha.com - May 20 at 6:02 PM
Zacks: Analysts Expect CytomX Therapeutics (CTMX) Will Announce Quarterly Sales of $19.30 MillionZacks: Analysts Expect CytomX Therapeutics (CTMX) Will Announce Quarterly Sales of $19.30 Million
www.americanbankingnews.com - May 20 at 4:35 AM
CytomX Therapeutics (CTMX) Presents At Bank Of America Merrill Lynch 2018 Healthcare Conference - SlideshowCytomX Therapeutics (CTMX) Presents At Bank Of America Merrill Lynch 2018 Healthcare Conference - Slideshow
seekingalpha.com - May 18 at 6:04 PM
Zacks: Brokerages Anticipate CytomX Therapeutics (CTMX) to Post -$0.37 Earnings Per ShareZacks: Brokerages Anticipate CytomX Therapeutics (CTMX) to Post -$0.37 Earnings Per Share
www.americanbankingnews.com - May 18 at 11:46 AM
CytomX up 6% premarket on CX-072 dataCytomX up 6% premarket on CX-072 data
seekingalpha.com - May 17 at 6:50 PM
CytomX Therapeutics (CTMX) PT Set at $40.00 by Cantor FitzgeraldCytomX Therapeutics (CTMX) PT Set at $40.00 by Cantor Fitzgerald
www.americanbankingnews.com - May 17 at 1:53 PM
CytomX Therapeutics Announces Presentations at 2018 ASCO Annual MeetingCytomX Therapeutics Announces Presentations at 2018 ASCO Annual Meeting
finance.yahoo.com - May 16 at 5:48 PM
Oppenheimer Research Analysts Lower Earnings Estimates for CytomX Therapeutics (CTMX)Oppenheimer Research Analysts Lower Earnings Estimates for CytomX Therapeutics (CTMX)
www.americanbankingnews.com - May 14 at 2:35 AM
BidaskClub Lowers CytomX Therapeutics (CTMX) to SellBidaskClub Lowers CytomX Therapeutics (CTMX) to Sell
www.americanbankingnews.com - May 11 at 9:13 PM
Zacks Investment Research Downgrades CytomX Therapeutics (CTMX) to HoldZacks Investment Research Downgrades CytomX Therapeutics (CTMX) to Hold
www.americanbankingnews.com - May 10 at 9:38 PM
CytomX Therapeutics (CTMX) Earns Buy Rating from CowenCytomX Therapeutics (CTMX) Earns Buy Rating from Cowen
www.americanbankingnews.com - May 10 at 9:37 PM
CytomX Therapeutics (CTMX) Announces  Earnings ResultsCytomX Therapeutics (CTMX) Announces Earnings Results
www.americanbankingnews.com - May 10 at 8:29 PM
CytomX Therapeutics (CTMX) Given a $40.00 Price Target by Cantor Fitzgerald AnalystsCytomX Therapeutics (CTMX) Given a $40.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - May 10 at 9:08 AM
CytomX Therapeutics: 1Q Earnings SnapshotCytomX Therapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 8:19 AM
CytomX Therapeutics Announces First Quarter 2018 Financial ResultsCytomX Therapeutics Announces First Quarter 2018 Financial Results
finance.yahoo.com - May 9 at 5:38 PM
CytomX Therapeutics (CTMX) Raised to Buy at Zacks Investment ResearchCytomX Therapeutics (CTMX) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - May 8 at 9:42 PM
CytomX to Present at the Bank of America Merrill Lynch 2018 Health Care ConferenceCytomX to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
finance.yahoo.com - May 7 at 5:42 PM
CytomX Therapeutics (CTMX) Given Consensus Recommendation of "Buy" by BrokeragesCytomX Therapeutics (CTMX) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 7 at 5:23 PM
CytomX Therapeutics (CTMX) CFO Sells $79,560.00 in StockCytomX Therapeutics (CTMX) CFO Sells $79,560.00 in Stock
www.americanbankingnews.com - May 2 at 8:15 PM
Insider Selling: CytomX Therapeutics (CTMX) CEO Sells 19,578 Shares of StockInsider Selling: CytomX Therapeutics (CTMX) CEO Sells 19,578 Shares of Stock
www.americanbankingnews.com - May 2 at 7:39 PM
Zacks: Brokerages Expect CytomX Therapeutics (CTMX) Will Post Quarterly Sales of $19.77 MillionZacks: Brokerages Expect CytomX Therapeutics (CTMX) Will Post Quarterly Sales of $19.77 Million
www.americanbankingnews.com - May 2 at 2:02 AM
CytomX Therapeutics to Announce First Quarter 2018 Financial ResultsCytomX Therapeutics to Announce First Quarter 2018 Financial Results
finance.yahoo.com - May 1 at 5:20 PM
CytomX Therapeutics (CTMX) Set to Announce Earnings on ThursdayCytomX Therapeutics (CTMX) Set to Announce Earnings on Thursday
www.americanbankingnews.com - April 26 at 2:34 AM
CytomX Therapeutics (CTMX) Cut to Hold at BidaskClubCytomX Therapeutics (CTMX) Cut to Hold at BidaskClub
www.americanbankingnews.com - April 18 at 10:05 AM
BidaskClub Downgrades CytomX Therapeutics (CTMX) to SellBidaskClub Downgrades CytomX Therapeutics (CTMX) to Sell
www.americanbankingnews.com - April 16 at 8:40 PM
CytomX Therapeutics (CTMX) Expected to Post Quarterly Sales of $19.77 MillionCytomX Therapeutics (CTMX) Expected to Post Quarterly Sales of $19.77 Million
www.americanbankingnews.com - April 15 at 2:14 AM
Zacks: Analysts Anticipate CytomX Therapeutics Inc (CTMX) to Announce -$0.30 Earnings Per ShareZacks: Analysts Anticipate CytomX Therapeutics Inc (CTMX) to Announce -$0.30 Earnings Per Share
www.americanbankingnews.com - April 13 at 9:19 PM
CytomX Therapeutics Inc (CTMX) Given Consensus Rating of "Buy" by AnalystsCytomX Therapeutics Inc (CTMX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - April 12 at 5:43 PM
CytomX Therapeutics (CTMX) Upgraded to "Hold" at BidaskClubCytomX Therapeutics (CTMX) Upgraded to "Hold" at BidaskClub
www.americanbankingnews.com - April 11 at 10:10 PM
Insider Selling: CytomX Therapeutics Inc (CTMX) CFO Sells 3,000 Shares of StockInsider Selling: CytomX Therapeutics Inc (CTMX) CFO Sells 3,000 Shares of Stock
www.americanbankingnews.com - April 4 at 4:16 PM
CytomX Therapeutics (CTMX) Lifted to Hold at ValuEngineCytomX Therapeutics (CTMX) Lifted to Hold at ValuEngine
www.americanbankingnews.com - April 3 at 5:16 PM
CytomX Therapeutics (CTMX) Lowered to "Buy" at BidaskClubCytomX Therapeutics (CTMX) Lowered to "Buy" at BidaskClub
www.americanbankingnews.com - March 30 at 1:06 PM
$19.77 Million in Sales Expected for CytomX Therapeutics Inc (CTMX) This Quarter$19.77 Million in Sales Expected for CytomX Therapeutics Inc (CTMX) This Quarter
www.americanbankingnews.com - March 29 at 4:36 AM
Frederick W. Gluck Sells 5,000 Shares of CytomX Therapeutics Inc (CTMX) StockFrederick W. Gluck Sells 5,000 Shares of CytomX Therapeutics Inc (CTMX) Stock
www.americanbankingnews.com - March 27 at 10:35 PM
CytomX Therapeutics (CTMX) Upgraded at BidaskClubCytomX Therapeutics (CTMX) Upgraded at BidaskClub
www.americanbankingnews.com - March 25 at 9:30 AM
FY2018 Earnings Forecast for CytomX Therapeutics Inc Issued By Cantor Fitzgerald (CTMX)FY2018 Earnings Forecast for CytomX Therapeutics Inc Issued By Cantor Fitzgerald (CTMX)
www.americanbankingnews.com - March 23 at 10:54 AM
CytomX Therapeutics Inc Forecasted to Earn FY2019 Earnings of ($1.66) Per Share (CTMX)CytomX Therapeutics Inc Forecasted to Earn FY2019 Earnings of ($1.66) Per Share (CTMX)
www.americanbankingnews.com - March 22 at 3:16 PM
CytomX Therapeutics (CTMX) Downgraded by Zacks Investment Research to SellCytomX Therapeutics (CTMX) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - March 12 at 9:54 PM
FY2022 Earnings Estimate for CytomX Therapeutics Inc (CTMX) Issued By OppenheimerFY2022 Earnings Estimate for CytomX Therapeutics Inc (CTMX) Issued By Oppenheimer
www.americanbankingnews.com - March 12 at 10:02 AM
$22.15 Million in Sales Expected for CytomX Therapeutics Inc (CTMX) This Quarter$22.15 Million in Sales Expected for CytomX Therapeutics Inc (CTMX) This Quarter
www.americanbankingnews.com - March 12 at 4:09 AM
Wedbush Weighs in on CytomX Therapeutics Incs Q1 2018 Earnings (CTMX)Wedbush Weighs in on CytomX Therapeutics Inc's Q1 2018 Earnings (CTMX)
www.americanbankingnews.com - March 12 at 2:32 AM
Zacks: Analysts Anticipate CytomX Therapeutics Inc (CTMX) Will Post Earnings of -$0.22 Per ShareZacks: Analysts Anticipate CytomX Therapeutics Inc (CTMX) Will Post Earnings of -$0.22 Per Share
www.americanbankingnews.com - March 10 at 3:22 PM
CytomX Therapeutics Inc Expected to Post FY2022 Earnings of $3.32 Per Share (CTMX)CytomX Therapeutics Inc Expected to Post FY2022 Earnings of $3.32 Per Share (CTMX)
www.americanbankingnews.com - March 9 at 4:32 PM
Immuno-Oncology Sector Deals Dominate 2017 Life Sciences Deal of the Year AwardsImmuno-Oncology Sector Deals Dominate 2017 Life Sciences Deal of the Year Awards
www.bizjournals.com - March 8 at 6:51 PM
CytomX beats by $0.49, beats on revenueCytomX beats by $0.49, beats on revenue
seekingalpha.com - March 8 at 6:51 PM
CytomX Therapeutics (CTMX) PT Raised to $40.00 at Bank of AmericaCytomX Therapeutics (CTMX) PT Raised to $40.00 at Bank of America
www.americanbankingnews.com - March 8 at 6:41 PM

SEC Filings

CytomX Therapeutics (NASDAQ:CTMX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

CytomX Therapeutics (NASDAQ:CTMX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

CytomX Therapeutics (NASDAQ CTMX) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.